Literature DB >> 32934368

Association between the size of healthcare facilities and the intensity of hypertension therapy: a cross-sectional comparison of prescription data from insurance claims data.

Shusuke Hiragi1,2, Noriaki Sato3,4, Eiichiro Uchino3,4, Tomohiro Kuroda5, Motoko Yanagita3,6.   

Abstract

Hypertension is a heterogeneous disease for which role sharing in treatment between specialized facilities and small clinics is needed for efficient healthcare provision. However, the Japanese healthcare system has a "free access" attribute; therefore, nobody can control treatment resource allocation. We aimed to describe the current situation of role sharing by comparing antihypertensive therapies among different types of medical facilities. We analyzed 1% sampled Japanese medical insurance claims data related to outpatient care as of October 2014. We divided the target patients into four groups according to the size of the facilities that issued the insurance claim for them. Among these groups, we compared the number of antihypertensive drugs and proportion of difficult-to-treat hypertensive cases and performed a stratified analysis. The proportion of patients with hypertension and diabetes mellitus receiving renin-angiotensin-aldosterone system inhibitors (RAASis) as the first-choice drug was also compared. We identified 3465, 1797, 2323, and 34,734 claims issued from large, medium-sized, small hospitals, and clinics, respectively. The mean number of hypertensive drugs was 1.96, 1.87, 1.81, and 1.69, respectively, and the proportion of difficult-to-treat hypertensive cases was 18.9, 17.0, 14.3, and 12.0%, respectively, with both showing significant differences. Stratified analysis showed similar results. The proportion of patients with hypertension and diabetes mellitus receiving RAASis as the first-choice drug was higher in large hospitals than in clinics. In conclusion, facility size is positively associated with the number of antihypertensive drugs and proportions of difficult-to-treat hypertensive cases. This finding describes the current role sharing situation of hypertension therapy in the Japanese healthcare system with a "free-access" attribute.

Entities:  

Keywords:  Administrative claim; Antihypertensive agents; Hypertension

Mesh:

Substances:

Year:  2020        PMID: 32934368      PMCID: PMC7872892          DOI: 10.1038/s41440-020-00549-2

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  2 in total

Review 1.  Calcium channel blocker in patients with chronic kidney disease.

Authors:  Shoko Ohno; Akira Ishii; Motoko Yanagita; Hideki Yokoi
Journal:  Clin Exp Nephrol       Date:  2021-11-08       Impact factor: 2.801

2.  Nationwide incidence of central retinal artery occlusion in Japan: an exploratory descriptive study using the National Database of Health Insurance Claims (2011-2015).

Authors:  Ai Kido; Hiroshi Tamura; Hanako Ohashi Ikeda; Masahiro Miyake; Shusuke Hiragi; Akitaka Tsujikawa
Journal:  BMJ Open       Date:  2020-09-24       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.